



JAPAN TOBACCO INC.  
1-1, Toranomom 4-chome, Minato-ku  
Tokyo 105-6927 JAPAN  
Phone: 03-6636-2914

FOR IMMEDIATE RELEASE

Tokyo, February 7, 2025

## Notice of the Announcement by a Subsidiary Company

**Japan Tobacco Inc. (JT) (TSE: 2914)** announces that Torii Pharmaceutical Co., Ltd. (Torii) (TSE:4551), our subsidiary company, made the following announcement today.

### (Attachment)

- Announcement Regarding Changes of Representative Director and Officers

###

*Japan Tobacco Inc. (JT) is a global company headquartered in Tokyo, Japan. It is listed on the primary section of the Tokyo Stock Exchange (ticker: 2914.T). JT Group has approximately 53,000 employees and 62 factories worldwide, operating in three business segments: tobacco, pharmaceutical, and processed food. Within the tobacco business, the largest segment, products are sold in over 130 markets and its flagship brands include Winston, Camel, MEVIUS, and LD. The Group is committed to investing in Reduced-Risk Products and markets its heated tobacco products under its Ploom brand.*

*Consumers, shareholders, employees, and society are the four stakeholder groups (4S) at the heart of all of JT Group's activities. Inspired by its "Fulfilling Moment, Enriching Life" purpose, the Group aims to ensure sustainable and valuable contributions to its stakeholders over the long term. In addition to our three business segments, this goal is also supported by D-LAB, the JT Group's corporate R&D initiative, set up to search and create added-value business opportunities. For more information, visit <https://www.jt.com/>.*

Contact: Yunosuke Miyata, Director  
Investor and Media Relations Division  
Japan Tobacco Inc.  
Tokyo: +81-3-6636-2914  
E-mail: [jt.media.relations@jt.com](mailto:jt.media.relations@jt.com)

Note: This document is a direct translation of the document released in Japanese. If there are any discrepancies between this document and the original Japanese version, the original Japanese version prevails.

**Announcement Regarding Changes of  
Representative Director and Officers**

Torii Pharmaceutical Co., Ltd. ("Torii") (TSE:4551) announced that at the meeting of its Board of Directors held today, Torii has informally decided on changes to its Representative Director and officers, etc., and also decided on personnel changes, as follows.

1. Change of Representative Director

(1) Reason for the Change

Due to change of management structure associated with the expiration of official term

(2) Names and positions of Representative Directors to be appointed and to retire

(To be newly appointed) Name: Nobumasa Kondo

New position: Representative Director, President and Chief Executive Officer

(To retire) Name: Goichi Matsuda

Former position: Representative Director, President and Chief Executive Officer

(3) Career Summary and number of shares of Torii held by the candidate for new Representative Director, President and Chief Executive Officer

Name	:	Nobumasa Kondo
Education	:	Graduate of the Faculty of Economics, Hitotsubashi University
Date of birth	:	September 28, 1968
Career summary	:	April 1992      Joined Japan Tobacco Inc. July 2012      Vice President, CSR Division of Japan Tobacco Inc. October 2015    Senior Manager of Business Planning Dept., Pharmaceutical Division of Japan Tobacco Inc. January 2016    Senior Manager of Business Administrative Dept., Pharmaceutical Division of Japan Tobacco Inc. March 2016      Vice President, Corporate Planning Dept. of Torii March 2019      Executive Officer, Head of Planning & Administration Group and Vice President, Corporate Planning Dept. of Torii October 2019    Executive Officer, Head of Planning & Administration Group of Torii March 2020      Senior Executive Officer, Head of Planning & Administration Group of Torii March 2024      Representative Director, Executive Deputy President of Torii (present post)

Number of shares of Torii : 5,606  
held

(4) Effective date

March 27, 2025

\*The appointment is scheduled to be formally decided at the 133rd Annual General Meeting of Shareholders, to be held on March 27, 2025, and the Board of Directors meeting that will take place after the General Meeting of Shareholders.

2. Changes in officers, etc. (Scheduled to take effect as of March 27, 2025)

(1) Director to be newly appointed

Director in charge of Pharmaceutical Marketing & Promotion Group	Katsunobu Fujiwara	(currently Senior Executive Officer, Head of Pharmaceutical Marketing & Promotion Group)
--	--------------------	--

\*The appointment is scheduled to be formally decided at the 133rd Annual General Meeting of Shareholders, to be held on March 27, 2025, and the Board of Directors meeting that will take place after the General Meeting of Shareholders.

(2) Director to be retired

Goichi Matsuda (currently Representative Director, President and Chief Executive Officer)

\*The retirement is scheduled to take effect at the end of the 133rd Annual General Meeting of Shareholders, to be held on March 27, 2025.

(3) Executive Officers to be newly appointed

Executive Officer, Head of Pharmaceutical Marketing & Promotion Group	Yuichiro Takeuchi	(currently Senior Vice President, Deputy Head of Pharmaceutical Marketing & Promotion Group, and Vice President, Marketing Planning Dept.)
Executive Officer, Head of Innovation Group	Gen Matsuo	(currently Senior Vice President, Deputy Head of Innovation Group)

(4) Executive Officer to be promoted

Senior Executive Officer, Head of Planning & Administration Group	Shinichiro Arikawa	(currently Executive Officer, Head of Planning & Administration Group)
---	--------------------	---

(5) Executive Officer to be retired

Atsuyuki Kakee (currently Senior Executive Officer, Head of Innovation Group)  
Katsunobu Fujiwara (currently Senior Executive Officer, Head of Pharmaceutical Marketing & Promotion Group)

\*Katsunobu Fujiwara is scheduled for appointment as a Director pending a vote of approval at the 133rd Annual General Meeting of Shareholders, scheduled to be held on March 27, 2025.

3. Other personnel changes (Scheduled to take effect as of March 27, 2025)

Vice President, Marketing Planning Dept.	Norihisa Asai	(currently Senior General Manager, Marketing Planning Dept.)
---	---------------	---

Contact for Torii Pharmaceutical Co., Ltd.:  
Corporate Planning Department  
(Public Relations)  
Torii Pharmaceutical Co., Ltd.  
Tokyo: +81-3-3231-6814  
E-mail: [webmaster@torii.co.jp](mailto:webmaster@torii.co.jp)

**List of New Directors**  
(Scheduled to be appointed as of March 27, 2025)

New Position	Name	Current position
Representative Director, President and Chief Executive Officer	Nobumasa Kondo*	Representative Director, Executive Deputy President
Director in Charge of Pharmaceutical Marketing & Promotion Group	Katsunobu Fujiwara*	Senior Executive Officer, Head of Pharmaceutical Marketing & Promotion Group
Outside Director, Audit and Supervisory Committee Member	Takaharu Matsumura	Same
Outside Director, Audit and Supervisory Committee Member	Mihoko Manabe	Same
Outside Director, Audit and Supervisory Committee Member	Kenichi Fujita	Same

- Notes: 1. Asterisk (\*) indicates that the appointment is scheduled to be formally decided at the 133rd Annual General Meeting of Shareholders, to be held on March 27, 2025, and the Board of Directors meeting that will take place after the General Meeting of Shareholders.
2. Directors Mr. Takaharu Matsumura, Ms. Mihoko Manabe and Mr. Kenichi Fujita are Outside Directors as defined in Article 2, Item 15 of the Companies Act. Furthermore, Directors Mr. Takaharu Matsumura, Ms. Mihoko Manabe and Mr. Kenichi Fujita are designated as Independent Directors as defined in Rule 436-2 of the Securities Listing Regulations of the Tokyo Stock Exchange.

<Director to be retired> Goichi Matsuda (currently Representative Director, President and Chief Executive Officer)

List of New Executive Officers  
(Scheduled to be appointed as of March 27, 2025)

Area of responsibility	Name	Current area of responsibility
Senior Executive Officer, Head of Planning & Administration Group	Shinichiro Arikawa	Executive Officer, Head of Planning & Administration Group
Executive Officer, Head of Pharmacovigilance & Quality Assurance Group	Noriaki Nishino	Same
Executive Officer, Head of Production Group	Koji Matsuda	Same
Executive Officer, Head of Pharmaceutical Marketing & Promotion Group	Yuichiro Takeuchi*	Senior Vice President, Deputy Head of Pharmaceutical Marketing & Promotion Group and Vice President, Marketing Planning Dept.
Executive Officer, Head of Innovation Group	Gen Matsuo*	Senior Vice President, Deputy Head of Innovation Group

Note: Asterisk (\*) indicates newly appointments that are scheduled to take effect on March 27, 2025.

<Executive Officer to be retired> Atsuyuki Kakee (currently Senior Executive Officer, Head of Innovation Group)